Insider · CIK 0001682068

Regnante Keith

Reports to the SEC for 3 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001682068

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-24	KROSKeros Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+60K sh	—	—	60,000
2026-02-18	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−4,739 sh	$16.35	−$77.5K	39,261
2025-02-18	KROSKeros Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+44K sh	—	—	44,000
2024-02-13	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+40K sh	—	—	40,000
2024-01-04	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−40K sh	—	—	53,622
2024-01-04	KROSKeros Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+40K sh	$16.00	+$640K	40,000
2024-01-04	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−40K sh	$45.29	−$1.81M	0
2023-11-04	KROSKeros Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+40K sh	$16.00	+$640K	40,000
2023-11-04	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−40K sh	$45.29	−$1.81M	0
2023-06-09	KROSKeros Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+20K sh	$16.00	+$320K	20,000
2023-06-09	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−16K sh	$45.03	−$720K	4,007
2023-06-09	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,428 sh	$46.46	−$66.3K	2,579
2023-06-09	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,579 sh	$47.25	−$122K	0
2023-06-09	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−20K sh	—	—	93,622
2023-06-08	KROSKeros Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+20K sh	$16.00	+$320K	20,000
2023-06-08	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−17.3K sh	$47.66	−$825K	2,699
2023-06-08	KROSKeros Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,699 sh	$48.65	−$131K	0
2023-06-08	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−20K sh	—	—	113,622
2023-02-16	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+40K sh	—	—	40,000
2022-01-21	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+50K sh	—	—	50,000
2021-01-10	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+49.2K sh	—	—	49,150
2020-04-07	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+18.4K sh	—	—	18,430
2020-04-07	KROSKeros Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+134K sh	—	—	133,622
2019-03-07	WVEWave Life Sciences, Inc.A Award	Chief Financial Officer	AAward	+13.5K sh	—	—	29,186
2019-02-19	WVEWave Life Sciences, Inc.S Sale	Chief Financial Officer	SSale	−1,298 sh	$36.84	−$47.8K	15,686
2018-09-24	WVEWave Life Sciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+29.5K sh	$20.89	+$616K	46,484
2018-09-24	WVEWave Life Sciences, Inc.S Sale	Chief Financial Officer	SSale	−29.5K sh	$55.00	−$1.62M	16,984
2018-09-24	WVEWave Life Sciences, Inc. · Share Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−29.5K sh	—	—	90,500
2018-02-16	WVEWave Life Sciences, Inc.S Sale	Chief Financial Officer	SSale	−316 sh	$51.85	−$16.4K	16,984
2018-01-23	WVEWave Life Sciences, Inc.A Award	Chief Financial Officer	AAward	+13K sh	—	—	17,300
2018-01-23	WVEWave Life Sciences, Inc. · Share Option (right to buy)A Award	Chief Financial Officer	AAward	+26K sh	—	—	26,000
2017-01-25	WVEWave Life Sciences, Inc.A Award	Chief Financial Officer	AAward	+4,300 sh	—	—	4,300
2017-01-25	WVEWave Life Sciences, Inc. · Share Option (right to buy)A Award	Chief Financial Officer	AAward	+8,600 sh	—	—	8,600
2016-08-16	WVEWave Life Sciences, Inc. · Share Option (right to buy)A Award	Chief Financial Officer	AAward	+120K sh	—	—	120,000

Recent filings

Accepted (ET)
Feb 264
Regnante Keith0001682068-26-000005
SEC(opens sec.gov)
Feb 204
Regnante Keith0001682068-26-000003
SEC(opens sec.gov)
Feb 194
Regnante Keith0001415889-25-004597
SEC(opens sec.gov)
Jan 244/A
Regnante Keith0001415889-25-002024
SEC(opens sec.gov)
Feb 154
Regnante Keith0001415889-24-004003
SEC(opens sec.gov)
Jan 84
Regnante Keith0001209191-24-001155
SEC(opens sec.gov)
Jun 124
Regnante Keith0001209191-23-036261
SEC(opens sec.gov)
Feb 174
Regnante Keith0001209191-23-010557
SEC(opens sec.gov)
Jan 254
Regnante Keith0001209191-22-004767
SEC(opens sec.gov)

Companies

Address

399 BINNEY STREET

CAMBRIDGE, MA, 02142